Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07811180

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

Conditions: Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 25
Sponsor: Vanderbilt University Medical Center

Location: Vanderbilt University Medical Center Nashville Tennessee

Summary

The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 or older * Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU * The participant or legally authorized representative must agree to the genetic analyses required as part of this study Exclusion Criteria: * Pregnant * Prisoner or in police custody * Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures * Hemoglobin less than 8 g/dL * Uncontrolled hyperglycemia (persistent blood glucose \>300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team * Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period * Unable to safely obtain vascular access required for study infusion and blood collection * Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team * Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives * Any reason which, in the opinion of the study investigator, adds additional risk to the patient

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07811180). StuddyBuddy aggregates publicly available trial information.